ArticleFrontiers in endocrinology2026
NGF administration is associated with increased GnRH immunoreactivity and a GnRH-associated phenotype in hypothalamic NSCs of aging mice.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Age-related decline in testosterone is closely associated with hypothalamic gonadotropin-releasing hormone (GnRH) neuron dysfunction. Nerve growth factor (NGF) has emerging roles in reproductive system. However, its effect on the differentiation of hypothalamic neural stem cells (htNSCs) into GnRH-associated phenotype remains unexplored. Methods: Male senescence-accelerated mouse P8 (SAMP8) models of age-related hypogonadism received a single intracerebroventricular injection of NGF at 6.25, 12.5, and 25 μg/kg. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone were measured 8 h, 24 h, 96 h, 7 d and 10 d post-injection. A kisspeptin agonist and antagonist were used in combination to interrogate whether NGF's endocrine effects depend on canonical kisspeptin signaling. Results: Central NGF administration significantly elevated serum FSH, LH, and testosterone levels in male SAMP8 mice, and these effects were not evidently mediated by canonical kisspeptin signaling. In the OVLT, NGF was associated with increased GnRH immunoreactivity and Sox2/GnRH co-localization, which may reflect phenotypic remodeling toward a GnRH-related cellular state. Conclusion: These findings suggest that central NGF administration may be associated with an increase in GnRH-immunoreactive cellular phenotypes, accompanied by enhanced the hypothalamic-pituitary-testicular axis endocrine output in male SAMP8 mice. Definitive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.